The Patent Finder

Guangzhou Cellprotek Pharmaceutical Co., Ltd.

14 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

0
Ending by 2030
Jul 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 23, 2027
    The maintenance fee for NEURO-PROTECTIVE AGENTS AND USES THEREOF (As Amended) (US 10,357,500) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
  • 1 fee due Apr 20, 2027
    The maintenance fee for 5α-androstane (alkyl)-3β, 5, 6β-triol injection and preparation method therefor (US 9,161,985) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
  • 2 fees due Aug 23 to 27, 2027 · next Aug 23
  • 1 fee due Oct 26, 2027
    The maintenance fee for Use of 5α-androstane-3β,5,6β-triol in preparation of neuroprotective drugs (US 9,320,743) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,809,309Use of 5α-androstane (alkyl)-3β,5,6β-triol in preparation of neuroprotective drugs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,265,8375α-androstane-3β,5,6β-triol injection and preparation method therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,161,9855α-androstane (alkyl)-3β, 5, 6β-triol injection and preparation method therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,320,743Use of 5α-androstane-3β,5,6β-triol in preparation of neuroprotective drugs
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,688,716Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,944,672Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,944,673Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,357,500NEURO-PROTECTIVE AGENTS AND USES THEREOF (As Amended)
In force
 · High confidence
In forceHigh confidence
US 10,835,539Neuro-Protective Agents and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,584,802Hexokinase 2-Specific Inhibitors for Use in Acute Central Nervous System Injury
In force
 · High confidence
In forceHigh confidence
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited